Literature DB >> 23074216

Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.

David A Gorelick1, Robert S Goodwin, Eugene Schwilke, David M Schwope, William D Darwin, Deanna L Kelly, Robert P McMahon, Fang Liu, Catherine Ortemann-Renon, Denis Bonnet, Marilyn A Huestis.   

Abstract

Oral cannabinoids are taken for medicinal or recreational purposes, yet little is known about tolerance to their effects after high-dose extended exposure. The development of tolerance to effects of around-the-clock oral synthetic Δ9-tetrahydrocannabinol (THC) (20 mg every 3.5-6 h) was evaluated in 13 healthy male daily cannabis smokers residing on a secure research unit: 40 mg on Day 1; 100 mg on Days 2-4; 120 mg on Days 5-6. Systolic and diastolic blood pressure (BP), heart rate, and symptoms of subjective intoxication (100 mm visual-analogue scales, VAS) were assessed the morning of Day 1 (before any oral THC), and on Days 2, 4 and 6, every 30 min for 3 h after the first morning THC dose. Morning subjective intoxication ratings increased from Days 1 to 2, and then declined on Days 4 and 6. The morning THC dose increased intoxication ratings on Day 2, but had less effect on Days 4 and 6, a pattern consistent with tolerance. THC lowered BP and increased heart rate over the six days. Plasma THC and 11-OH-THC concentrations increased significantly over the first five days of dosing. Six days of around-the-clock, oral THC produced tolerance to subjective intoxication, but not to cardiovascular effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23074216      PMCID: PMC3584989          DOI: 10.1093/jat/bks081

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  23 in total

1.  Effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O]water: effect in occasional and chronic users.

Authors:  Laura L Boles Ponto; Daniel S O'Leary; Julie Koeppel; Robert I Block; G Leonard Watkins; John C W Richmond; Christine A Ward; Dean A Clermont; Beth A Schmitt; Richard D Hichwa
Journal:  J Clin Pharmacol       Date:  2004-07       Impact factor: 3.126

2.  Behavioral and biologic aspects of marijuana use.

Authors:  J H Mendelson; T F Babor; J C Kuehnle; A M Rossi; J G Bernstein; N K Mello; I Greenberg
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

Review 3.  Cardiovascular system effects of marijuana.

Authors:  Reese T Jones
Journal:  J Clin Pharmacol       Date:  2002-11       Impact factor: 3.126

4.  Delirium following ingestion of marijuana present in chocolate cookies.

Authors:  Charles André; Jorge A Jaber-Filho; Rafael M A Bento; Lúcia M P Damasceno; Francisco R Aquino-Neto
Journal:  CNS Spectr       Date:  2006-04       Impact factor: 3.790

5.  Clinical studies of cannabis tolerance and dependence.

Authors:  R T Jones; N Benowitz; J Bachman
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

6.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

Authors:  M A Huestis; D A Gorelick; S J Heishman; K L Preston; R A Nelson; E T Moolchan; R A Frank
Journal:  Arch Gen Psychiatry       Date:  2001-04

7.  The first night effect: an EEG study of sleep.

Authors:  H W Agnew; W B Webb; R L Williams
Journal:  Psychophysiology       Date:  1966-01       Impact factor: 4.016

8.  A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations.

Authors:  Mary E Lynch; Judee Young; Alexander J Clark
Journal:  J Pain Symptom Manage       Date:  2006-11       Impact factor: 3.612

9.  Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review.

Authors:  Jayme Cotter
Journal:  Oncol Nurs Forum       Date:  2009-05-01       Impact factor: 2.172

10.  Cannabis psychosis following bhang ingestion.

Authors:  H R Chaudry; H B Moss; A Bashir; T Suliman
Journal:  Br J Addict       Date:  1991-09
View more
  25 in total

1.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

Review 2.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 4.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

5.  Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Authors:  Evan S Herrmann; Ziva D Cooper; Gillinder Bedi; Divya Ramesh; Stephanie C Reed; Sandra D Comer; Richard W Foltin; Margaret Haney
Journal:  Psychopharmacology (Berl)       Date:  2016-04-16       Impact factor: 4.530

6.  Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test.

Authors:  Rebecca A LaFleur; Ronald P Wilson; Daniel J Morgan; Angela N Henderson-Redmond
Journal:  Neuroreport       Date:  2018-04-11       Impact factor: 1.837

7.  Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication.

Authors:  Jodi M Gilman; Meryem A Yücel; Gladys N Pachas; Kevin Potter; Nina Levar; Hannah Broos; Eve M Manghis; Randi M Schuster; A Eden Evins
Journal:  Neuroimage       Date:  2019-05-07       Impact factor: 6.556

Review 8.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 9.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

10.  Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.

Authors:  Dayong Lee; Ryan Vandrey; Damodara R Mendu; Sebastien Anizan; Garry Milman; Jeannie A Murray; Allan J Barnes; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-08-12       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.